BRAF and melanoma: In the CaCTUS study, patients with BRAF mutant melanoma on the intervention arm switch from targeted treatment to immunotherapy when there is evidence of molecular response, as defined by a decrease in mutant BRAF VAF of ≥80% by ddPCR.